Viridian: Positive Data from Ongoing Phase 1/2 Trial in Chronic Thyroid Eye Disease

 VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg –

- Ongoing THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian’s confidence in 5-dose regimen and key stakeholder feedback on evolving TED treatment paradigm -

- THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in third quarter 2023 –

- 3 mg/kg data support low-volume subcutaneous (SC) dosing profile for Company’s SC candidates in TED -

- Viridian plans to select lead SC program candidate by year-end 2023; VRDN-001 SC IND amendment and VRDN-003 IND submitted to the FDA –

- Conference call and webcast to be held today, Monday, July 10th at 5:00 p.m. ET -

The Company will host a conference call today at 5:00 p.m. ET to discuss the topline data and program updates in TED. The dial-in number for the conference call is 1-888-330-3622 for domestic participants and 1-646-960-0662 for international participants. The conference ID is 3961606.

A live webcast of the conference call can be accessed through the "Events" page in the Investors section of the Viridian Therapeutics website. Following the live webcast, an archived version of the call will also be available on the website.

https://finance.yahoo.com/news/viridian-announces-positive-data-ongoing-200100530.html